1. Search Result
Search Result
Results for "

hp-

" in MedChemExpress (MCE) Product Catalog:

81

Inhibitors & Agonists

3

Biochemical Assay Reagents

6

Peptides

7

MCE Kits

4

Natural
Products

41

Recombinant Proteins

11

Isotope-Labeled Compounds

34

Antibodies

10

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101103
    HP-β-CD
    30+ Cited Publications

    (2-Hydroxypropyl)-β-cyclodextrin

    Biochemical Assay Reagents Cancer
    HP-β-CD ((2-Hydroxypropyl)-β-cyclodextrin) is a widely used drug delivery vehicle to improve the stability and bioavailability.
    HP-β-CD
  • HY-101588
    Gefapixant
    2 Publications Verification

    MK-7264; AF-219

    P2X Receptor Inflammation/Immunology
    Gefapixant is an orally active and potent purinergic P2X3 receptor (P2X3R) antagonist, with IC50 values of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. Gefapixant can be used for the research of chronic cough and knee osteoarthritis .
    Gefapixant
  • HY-114364
    UDP-Galactose disodium
    4 Publications Verification

    Endogenous Metabolite P2Y Receptor Metabolic Disease
    UDP-Galactose disodium is a monosaccharide and a key glycosyl donor molecule in cells that participates in nucleotide sugar metabolism. UDP-Galactose disodium is the natural agonist of the P2Y14 receptor coupled to Gi proteins in the immune system (IC50 = 0.67 μM, hP2Y14). UDP-Galactose disodium can be used to study cell signal transduction and substance metabolism .
    UDP-Galactose disodium
  • HY-123857
    JNJ-55308942
    2 Publications Verification

    P2X Receptor Neurological Disease Inflammation/Immunology
    JNJ-55308942 is a high-affinity, selective, brain-penetrant P2X7 functional antagonist (hP2X7: IC50=10 nM, Ki=7.1 nM; rP2X7: IC50=15 nM, Ki=2.9 nM). JNJ-55308942 is orally bioavailable, binds to brain P2X7 and blocks IL-1β release from adult rodent brain .
    JNJ-55308942
  • HY-17410
    Iloperidone
    2 Publications Verification

    hp 873

    5-HT Receptor Dopamine Receptor Neurological Disease
    Iloperidone (HP 873) is a D2/5-HT2 receptor antagonist. Iloperidone is an atypical antipsychotic for the schizophrenia symptoms .
    Iloperidone
  • HY-101588A
    Gefapixant citrate
    2 Publications Verification

    MK-7264 citrate; AF-219 citrate

    P2X Receptor Inflammation/Immunology
    Gefapixant citrate is an orally active and potent purinergic P2X3 receptor (P2X3R) antagonist, with IC50 values of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. Gefapixant citrate can be used for the research of chronic cough and knee osteoarthritis .
    Gefapixant citrate
  • HY-136026

    BLU-5937

    P2X Receptor Inflammation/Immunology
    Camlipixant (BLU-5937) a potent, selective, non-competitive and orally active P2X3 homotrimeric receptor antagonist with an IC50 of 25 nM against hP2X3 homotrimeric. Camlipixant shows potent anti-tussive effect and no taste alteration. Camlipixant can be used for the research of unexplained, refractory chronic cough .
    Camlipixant
  • HY-15568
    A-317491
    5 Publications Verification

    P2X Receptor Neurological Disease Inflammation/Immunology
    A-317491 is a potent, selective and non-nucleotide antagonist of P2X3 and P2X2/3 receptors, with Kis of 22, 22, 9, and 92 nM for hP2X3, rP2X3, hP2X2/3, and rP2X2/3, respectively. A-317491 is highly selective (IC50>10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 reduces inflammatory and neuropathic pain by blocking P2X3 and P2X2/3 receptor-mediated calcium flux .
    A-317491
  • HY-117508

    P2X Receptor Neurological Disease
    JNJ-54175446 is a potent and selective brain penetrant P2X7 receptor antagonist, with pIC50s of 8.46 and 8.81 for hP2X7 receptor and rP2X7 receptor, respectively.
    JNJ-54175446
  • HY-W050088

    hp 549

    Drug Derivative Neurological Disease Inflammation/Immunology
    Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .
    Isoxepac
  • HY-150524

    Endogenous Metabolite P2Y Receptor Metabolic Disease
    UDP-Galactose is a monosaccharide and a key glycosyl donor molecule in cells that participates in nucleotide sugar metabolism. UDP-Galactose is the natural agonist of the P2Y14 receptor coupled to Gi proteins in the immune system (IC50 = 0.67 μM, hP2Y14). UDP-Galactose can be used to study cell signal transduction and substance metabolism .
    UDP-Galactose
  • HY-151480

    STAT Apoptosis Cancer
    HP590 is an orally active, novel and potent STAT3 inhibitor (STAT3 luciferase activity: IC50=27.8 nM; ATP inhibition: IC50=24.7 nM). HP590 shows anti-proliferative activity to gastric cancer cells and induces apoptosis .
    HP590
  • HY-121870

    Larocaine

    Drug Derivative Cytochrome P450 Neurological Disease
    Dimethocaine (Larocaine) is a cocaine derivative and ester-type local anesthetic. Dimethocaine is metabolized by hP450 1A2, 2C19, 2D6, and 3A4 in vitro. Dimethocaine exhibits locomotor-promoting, reinforcing, and anxiogenic effects .
    Dimethocaine
  • HY-E70058

    α-1-3,4 FucT; hp3/4FT

    Endogenous Metabolite Metabolic Disease
    alpha-1,3/4-Fucosyltransferase (α1,3/4FucT) (EC 2.4.1.65) (Hp3/4FT) can be found in Helicobacter pylori. alpha-1,3/4-Fucosyltransferase (α1,3/4FucT) catalyzes fucose transfer from donor GDP-beta-l-fucose to the GlcNAc .
    α-1-3,4 Fucosyltransferase, helicobacter pylori
  • HY-15568A
    A-317491 sodium salt hydrate
    5 Publications Verification

    P2X Receptor Neurological Disease Inflammation/Immunology
    A-317491 sodium salt hydrate is a potent, selective and non-nucleotide antagonist of P2X3 and P2X2/3 receptors, with Kis of 22, 22, 9, and 92 nM for hP2X3, rP2X3, hP2X2/3, and rP2X2/3, respectively. A-317491 sodium salt hydrate is highly selective (IC50>10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 sodium salt hydrate reduces inflammatory and neuropathic pain by blocking P2X3 and P2X2/3 receptor-mediated calcium flux .
    A-317491 sodium salt hydrate
  • HY-175729

    CDK Cancer
    Cyclin A/B RxL-IN-1 is a inhibitor targeting the Cyclin A/B RxL interaction at the hydrophobic patch (HP). Cyclin A/B RxL-IN-1 inhibits Cyclin A with an IC50 of 0.12 μM. Cyclin A/B RxL-IN-1 demonstrates antitumor efficacy in mouse cell line-derived xenograft (CDX) models. CDK-IN-19 can be used for the study of E2F-driven cancers such as small-cell lung cancer (SCLC) .
    Cyclin A/B RxL-IN-1
  • HY-E70064A

    hp3FT

    Glycosyltransferase Others
    Helicobacter pylori alpha-1,3-fucosyltransferase (Hp3FT) catalyzes the glycosyl addition of fucose from the donor GDP-fucose to the acceptor N-acetyllactosamine .
    Helicobacter pylori alpha-1,3-fucosyltransferase
  • HY-154840

    4-Thio-UTP tetralithium

    P2Y Receptor Inflammation/Immunology
    4-Thiouridine 5′-triphosphate (4-Thio-UTP) tetrasodium (Compound 15) is a UTP analog and potent P2Y2 and P2Y4 agonist with EC50 values of 35 and 350 nM for hP2Y2 and hP2Y4, respectively. 4-Thiouridine 5′-triphosphate tetrasodium can be used in cross-linking experiments and transcriptional complex labeling studies .
    4-Thiouridine 5′-triphosphate tetralithium
  • HY-W011246

    hp 029; Hydroxytacrine maleate

    Cholinesterase (ChE) Neurological Disease
    Velnacrine maleate (HP 029) is an orally active cholinesterase inhibitor that can be used for the research of Alzheimer's disease .
    Velnacrine maleate
  • HY-127165

    hp 029 free base; Hydroxytacrine

    Cholinesterase (ChE) Neurological Disease
    Velnacrine (HP 029 free base) is an inhibitor for acetylcholinesterase (AChE), with an IC50 of 3.27 μM. Velnacrine reverses the Scopolamine (HY-N0296)-induced amnesia in rat models, and exhibits acute toxicity with LD50 of 65 mg/kg .
    Velnacrine
  • HY-17410S

    Isotope-Labeled Compounds 5-HT Receptor Dopamine Receptor Neurological Disease
    Iloperidone-d3 is the deuterium labeled Iloperidone. Iloperidone (HP 873) is a D2/5-HT2 receptor antagonist. Iloperidone is an atypical antipsychotic for the schizophrenia symptoms .
    Iloperidone-d3
  • HY-127165S2

    hp 029-d4 hydrochloride; Hydroxytacrine-d4 hydrochloride

    Isotope-Labeled Compounds Others
    Velnacrine-d4 (hydrochloride) is deuterium labeled Velnacrine.
    Velnacrine-d4 hydrochloride
  • HY-178006

    P2Y Receptor Neurological Disease
    MRS4917 is an orally active, potent selective P2Y14 receptor (hP2Y14R) antagonist (IC50 = 2.88 nM, Ki = 1.67 nM) that shows >18,000 fold selectivity against P2Y6R (IC50 = 54 μM). MRS4917 demonstrates oral efficacy in reversing established mechanoallodynia in the chronic constriction injury (CCI) mouse model, while having no effect on thermoregulation. MRS4917 can be used for neurological diseases research .
    MRS4917
  • HY-114364S

    Isotope-Labeled Compounds Others
    UDP-α-D-Galactose- 13C disodium is the 13C labeled UDP-α-D-Galactose disodium. UDP-Galactose disodium is a monosaccharide and a key glycosyl donor molecule in cells that participates in nucleotide sugar metabolism. UDP-Galactose disodium is the natural agonist of the P2Y14 receptor coupled to Gi proteins in the immune system (IC50 = 0.67 μM, hP2Y14). UDP-Galactose disodium can be used to study cell signal transduction and substance metabolism .
    UDP-α-D-Galactose-13C disodium
  • HY-171951

    Liposome Others
    31hP is an asymmetric A 3 lipid. 31hP can facilitate in vivo luciferase expression. 31hP can be rapidly degraded in the presence of esterase owing to two biocleavable ester bonds. 31hP can be used in the synthesis of lipid nanoparticles (LNPs) .
    31hP
  • HY-179446

    Histone Methyltransferase Cancer
    HP1-IN-2 (Compound (R)-18) is a HP1/H3K9me3 interaction inhibitor with an IC50 of 18.1 μM. HP1-IN-2 can be used for studying various cancers with overexpression of HP1 .
    HP1-IN-2
  • HY-106508

    hp 129; P 71-0129

    PAI-1 Inflammation/Immunology
    Fendosal (HP 129) is an orally active, potent non-steroidal anti-inflammatory agent. Fendosal (HP 129) is also an inhibitor of Plasminogen activator inhibitor-1 (PAI-1) .
    Fendosal
  • HY-170598

    PROTACs SARS-CoV Virus Protease Infection
    HP211206 is a SARS-CoV-2 main protease (M pro) PROTAC degrader. HP211206 effectively degrades SARS-CoV-2 M pro and its drug-resistant mutants. HP211206 has an IC50 of 181.9 nM and a DC50 of 621 nM for M pro. HP211206 has antiviral activity. (Pink: H117 (HY-170599); Black: linker (HY-B0236); Blue: E3 ligase ligand (HY-41547)) .
    HP211206
  • HY-17410A

    hp 873 hydrochloride

    5-HT Receptor Dopamine Receptor Neurological Disease
    Iloperidone hydrochloride (HP 873 hydrochloride) is a D2/5-HT2 receptor antagonist. Iloperidone hydrochloride is an atypical antipsychotic for the schizophrenia symptoms .
    Iloperidone hydrochloride
  • HY-P5310

    Biochemical Assay Reagents Others
    IgA1 Peptide HP is an IgA1 hinge region peptide .
    IgA1 Peptide HP
  • HY-W050088S

    hp 549-d6

    Isotope-Labeled Compounds Drug Derivative Neurological Disease Inflammation/Immunology
    Isoxepac-d6 (HP 549-d6) is the deuterium labeled Isoxepac (HY-W050088). Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .
    Isoxepac-d6
  • HY-154840A

    4-Thio-UTP tetrasodium

    P2Y Receptor Inflammation/Immunology
    4-Thiouridine 5′-triphosphate (4-Thio-UTP) tetralithium (Compound 15) is a UTP analog and potent P2Y2 and P2Y4 agonist with EC50 values of 35 and 350 nM for hP2Y2 and hP2Y4, respectively. 4-Thiouridine 5′-triphosphate tetralithium can be used in cross-linking experiments and transcriptional complex labeling studies .
    4-Thiouridine 5′-triphosphate tetrasodium
  • HY-W097612

    P2X Receptor Others
    P2X4 antagonist-5 (compound 63) is a control compound for P2X4 antagonists (IC50>100 μM, hP2X4) .
    P2X4 antagonist-5
  • HY-156220

    P2Y Receptor Neurological Disease Inflammation/Immunology
    MRS4654 is an efficient and neutral P2Y14R (hP2Y14R IC50 = 15.0 nM, mP2Y14R IC50 = 18.6 nM) antagonist. MRS4654 has analgesic and anti-inflammatory effects. MRS4654 can be used for research on asthma and neuropathic pain .
    MRS4654
  • HY-156203

    P2Y Receptor Inflammation/Immunology
    MRS4608 (Compound 17) is a selective P2Y14 receptor antagonist with IC50 values of 20 (hP2Y14R) and 21.4 nM (mP2Y14R). MRS4608 has anti-inflammatory activity and can reduce the infiltration of eosinophils. MRS4608 can be used for the researches of inflammation and immunology, such as asthma .
    MRS4608
  • HY-178461

    Lactate Dehydrogenase Cancer
    LDHA-IN-10 (Compound HP19) is a Lactate Dehydrogenase-A (LDHA) inhibitor with an IC50 value of 5.2 μM. LDHA-IN-10 reduces lactate production and ATP levels, inhibiting the proliferation of pancreatic cancer cell line PANC-1. LDHA-IN-10 induces G1/S cell cycle arrest and promotes apoptosis. LDHA-IN-10 is promising for research of pancreatic ductal adenocarcinoma (PDAC) .
    LDHA-IN-10
  • HY-179373

    P2X Receptor Cardiovascular Disease Neurological Disease Cancer
    UB-MBX-46 is a potent and selective P2X7 receptor antagonist with IC50s of 0.514 nM (hP2X7R), 40.6 nM (rP2X7R), and 4.52 nM (mP2X7R), respectively. UB-MBX-46 interacts with the classical allosteric pocket of the human P2X7 receptor. UB-MBX-46 can be used for cancer, atherosclerosis, and neurode generation research .
    UB-MBX-46
  • HY-168117

    Bacterial Infection
    HP-101 is a cell-permeable dual-substrate inhibitor of HPPK with activity against Gram-positive bacteria. .
    HP-101
  • HY-146564A

    Glucocorticoid Receptor Inflammation/Immunology
    HP210 is a selective glucocorticoid receptor modulator (SGRM). HP210 can inhibit the mRNA expression of IL-1β and IL-6. HP210 has the potential to study inflammation-related diseases .
    HP210
  • HY-145691

    FLT3 Cancer
    HP1142 is a potent and selective inhibitor of FLT3 receptor tyrosine kinase (FLT3/ITD mutation). HP1142 is a benzoimidazole scaffold-based compound. HP1142 has the potential for the research of FLT3/ITD leukemia .
    HP1142
  • HY-145690

    FLT3 Cancer
    HP1328 is a potent inhibitor of FLT3 receptor tyrosine kinase (FLT3/ITD mutation). HP1328 is a benzoimidazole scaffold-based compound. HP1328 significantly reduces the leukemia burden and prolongs the survival of mice with FLT3/ITD leukemia .
    HP1328
  • HY-P10539

    Bacterial Infection
    Hp1404 is a novel cationic antimicrobial peptide. Hp1404 has specific inhibitory activity against Gram-positive bacteria, including Staphylococcus aureus (MRSA) resistant to Laburnetin (HY-N7382). Hp1404 has antimicrobial activity, low toxicity, and is not prone to drug resistance, and can be used in the research of antimicrobial agents .
    Hp1404
  • HY-106016

    Cholinesterase (ChE) Others
    HP 184 is an acetylcholine release (ChE) stimulator whose ADME properties can be altered by replacing hydrogen with deuterium .
    HP 184
  • HY-146564

    NF-κB Inflammation/Immunology
    R-HP210 acts on the NF-κB mediated tethered transrepression function (IC50=3.80 μM). R-HP210 represses the LPS-induced transcription of a variety of proinflammatory genes such as IL-1β, IL-6 and COX-2. R-HP210 does not induce the transactivation functions of Glucocorticoids (GCs) .
    R-HP210
  • HY-146561

    Glucocorticoid Receptor NF-κB Inflammation/Immunology
    S-HP210 is a potent and selective glucocorticoid receptor (GR) with an IC50 value of 1.92 μM for NF-κB transrepression (TR). S-HP210 represses the LPS-induced transcription of a variety of proinflammatory genes such as IL-1β, IL-6 and COX-2. S-HP210 is nontoxic at effective doses against mouse fibroblasts 3T3 cells .
    S-HP210
  • HY-RS06331

    Small Interfering RNA (siRNA) Others

    HP Human Pre-designed siRNA Set A contains three designed siRNAs for HP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HP Human Pre-designed siRNA Set A
    HP Human Pre-designed siRNA Set A
  • HY-135427

    hp-290; NXX-066

    Drug Derivative Cholinesterase (ChE) Neurological Disease
    Quilostigmine (HP-290) is an orally active Physostigmine (HY-N6608) analogue, acetylcholinesterase (IC50: 148 nM for rat brain acetylcholinesterase) inhibitor. Quilostigmine has a long-lasting effect on tremors. Quetiapine can be used in the research of Alzheimer's disease .
    Quilostigmine
  • HY-17410R

    hp 873 (Standard)

    5-HT Receptor Dopamine Receptor Reference Standards Neurological Disease
    Iloperidone (Standard) is the analytical standard of Iloperidone. This product is intended for research and analytical applications. Iloperidone (HP 873) is a D2/5-HT2 receptor antagonist. Iloperidone is an atypical antipsychotic for the schizophrenia symptoms .
    Iloperidone (Standard)
  • HY-RS06332

    Small Interfering RNA (siRNA) Others

    HP1BP3 Human Pre-designed siRNA Set A contains three designed siRNAs for HP1BP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HP1BP3 Human Pre-designed siRNA Set A
    HP1BP3 Human Pre-designed siRNA Set A
  • HY-17410S2

    hp 873-13C,d3

    Isotope-Labeled Compounds Dopamine Receptor 5-HT Receptor Neurological Disease
    Iloperidone- 13C,d3 (HP 873- 13C,d3) is 13C labeled Iloperidone. Iloperidone (HP 873) is a D2/5-HT2 receptor antagonist. Iloperidone is an atypical antipsychotic for the schizophrenia symptoms .
    Iloperidone-13C,d3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: